Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in post-ICI HCC
NCT04826406Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04826406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826406.